Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA.
Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):69-76. doi: 10.1097/QAI.0000000000002823.
Impaired lung function is common among older children with perinatally acquired HIV (PHIV) who initiated antiretroviral therapy (ART) late in childhood. We determined the prevalence of abnormal spirometry and cofactors for impaired lung function among school-age children with PHIV who initiated ART when aged 12 months or younger.
Children who received early ART in the Optimizing Pediatric HIV-1 Therapy study in Kenya and underwent spirometry at school age.
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured. Abnormal spirometry was defined as follows: obstructive (FEV1/FVC <1.64 z score [zFEV1/FVC]) and restricted (zFVC <1.64 with zFEV1/FVC ≥1.64). Characteristics, including anthropometric and HIV-related data, were ascertained in infancy and at school age. Caregiver carbon monoxide exposure served as a proxy for school-age child exposure. Linear regression determined associations of cofactors with lung function.
Among 40 children, the median age was 5 months at ART initiation and 8.5 years at spirometry. The mean zFEV1, zFVC, and zFEV1/FVC (SD) were 0.21 (1.35), 0.31 (1.22), and -0.24 (0.82), respectively. Five (13%) children had abnormal spirometry. Spirometry z scores were significantly lower among children with pre-ART pneumonia, WHO HIV stage 3/4, higher HIV RNA at 6 months after ART initiation, low anthropometric z scores, and higher carbon monoxide exposure.
Most of the children with PHIV who initiated ART at age 12 months or younger had normal spirometry, suggesting that ART in infancy preserved lung function. However, 13% had abnormal spirometry despite early ART. Modifiable factors were associated with impaired lung function, providing potential targets for interventions to prevent chronic lung disease.
在儿童期晚期开始抗逆转录病毒治疗(ART)的围生期获得人类免疫缺陷病毒(PHIV)的大龄儿童中,肺功能受损很常见。我们确定了在肯尼亚的优化儿科 HIV-1 治疗研究中,12 个月或更小年龄开始 ART 的 PHIV 学龄儿童中,肺功能障碍的流行率和肺功能障碍的相关因素。
在肯尼亚的优化儿科 HIV-1 治疗研究中,接受早期 ART 并在学龄期进行肺功能测定的儿童。
测量 1 秒用力呼气量(FEV1)和用力肺活量(FVC)。异常肺功能定义如下:阻塞性(FEV1/FVC <1.64 z 分数[zFEV1/FVC])和限制性(zFVC <1.64,同时 zFEV1/FVC ≥1.64)。在婴儿期和学龄期确定了特征,包括人体测量和 HIV 相关数据。儿童的一氧化碳暴露情况由父母的一氧化碳暴露情况替代。线性回归确定了相关因素与肺功能的关联。
在 40 名儿童中,ART 开始时的中位年龄为 5 个月,肺功能测定时的中位年龄为 8.5 岁。平均 zFEV1、zFVC 和 zFEV1/FVC(标准差)分别为 0.21(1.35)、0.31(1.22)和-0.24(0.82)。5 名(13%)儿童的肺功能异常。与未接受 ART 时患有肺炎、WHO HIV 分期 3/4、ART 开始后 6 个月时 HIV RNA 较高、人体测量 z 评分较低和一氧化碳暴露较高的儿童相比,这些儿童的肺功能 z 评分明显较低。
大多数在 12 个月或更小年龄开始 ART 的 PHIV 儿童的肺功能正常,这表明婴儿期的 ART 可以保护肺功能。然而,尽管进行了早期 ART,仍有 13%的儿童的肺功能异常。可改变的因素与肺功能障碍相关,为预防慢性肺病提供了潜在的干预靶点。